If you liked this article you might like

Allergan's Boldness may not be Limited to Tobira Deal
16 Biopharma Companies Besides Medivation That Are Attractive Targets
Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium
Alder (ALDR) Stock Spikes on Successful Migraine Prevention Study